Completed PHASE4 INTERVENTIONAL 2-arm NCT06351917

Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain

Sponsor: RDC Clinical Pty Ltd

Interventions Placebo topical spray solution PlexoZome® Levagen® topical spray solution

Updated 5 times since 2024 Last updated: Dec 3, 2024 Started: Apr 24, 2024 Primary completion: Jun 18, 2024 Completion: Jun 18, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06351917, this PHASE4 trial focuses on Knee Joint Pain and remains completed. Sponsored by RDC Clinical Pty Ltd, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Nov 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE4

Status: Not Yet Recruiting → Active Not Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RDC Clinical Pty Ltd

Data source: RDC Clinical Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brisbane, Australia